The therapy is based on a gene for hepatocyte growth factor applied as a plasmid. Its intended action is the gene therapy of peripheral vascular diseases including severe ischemic limbs. Anges has exclusive distribution agreements with Mitsubishi Tanabe Pharma Co., Ltd. in Japan and the United States.
Anges MG news release, January 22, 2018
Anges MG applies to MHLW for preliminary approval of HGF gene therapy